A Meta-analysis Of The Clinical Efficacy And Safety Of Olaparib Maintenance Therapy In Patients With Recurrent Epithelial Ovarian Cancer

Objective: To evaluate the clinical efficacy and safety of olaparib maintenance therapy in patients with recurrent epithelial ovarian cancer.Methods:By searchig PubMed,Cochrane Library,Embase,CNKI,CBM and WanFang database until November 2017 collect relative randomized controlled trials that evalueted the clinical efficacy and safety in patients with recurrent epithelial ovarian cancer.The methodological quality of the included studies were evaluated according to the criteria of Cochrane Handbook for Systematic Reviews of interventions,then the relevant data extracted,and RevMan5.3 software was used for data analysis.Results: Three phase II and one phase III randomized clinical trials(RCTs)including 785 patients were ultimately included.The meta-analysis showed:olaparib maintenance therapy significantly improved recurrent epithelial ovarian cancer patients progression free survival(progression free survival,PFS)[HR = 0.43,95% CI(0.30,0.63),P<0.0001],especially in patients with BRCA mutations[HR = 0.33,95% CI(0.18,0.61),P = 0.0004).Safety: the common adverse events caused by olaparib include nausea,vomiting,exhaustion,anemia,etc,which were mild,less toxic,and tolerable.Conclusion: Olaparib maintenance therapy can prolong PFS in patients with recurrent epithelial ovarian cancer,improving the living quality,but to improve overall survival,evidence is insufficient.